The intestine renews itself constantly, yet that repair system becomes less capable with age. A new mouse study in Nature Aging moves the explanation beyond wear inside the stem cells themselves. It finds that signals circulating through an older body can push young intestinal stem cells toward an older, less regenerative state, with inflammation disrupting how those cells use fat for energy.
The result is a mechanistic map, not a human therapy. Researchers at Albert Einstein College of Medicine and collaborating institutions combined old and young mice, intestinal organoids, genetic knockouts, metabolic measurements and drug experiments. Their evidence connects an inflammatory signal, tumor necrosis factor, to its receptor TNFR1 on intestinal epithelial cells and then to reduced fatty-acid oxidation and impaired regeneration.
A signal from the aging environment
The study began with a basic age difference. Small-intestinal crypts from older mice formed roughly 30 percent fewer organoids than crypts from younger mice. Older animals also showed lower stem-cell proliferation and fared worse after gut-targeted radiation, a demanding test of the intestine’s ability to repair its lining.
To ask whether the cause resided only inside old cells, the team used heterochronic parabiosis, surgically joining young and old mice so they shared a circulation. Young mice exposed to the older environment later produced fewer intestinal organoids than young mice paired with young animals. That experiment points to a circulating or systemically induced influence, although parabiosis also shares housing conditions and can introduce persistent surgical stress.
The investigators then narrowed the pathway. Blocking TNF or interferon-gamma in old mice improved organoid formation, while blocking interleukin-1 beta did not. Most specifically, young mice engineered to lack TNFR1 in intestinal epithelial cells were protected from the old environment’s suppressive effect when paired with old animals. The knockout does not explain every contributor to gut aging, but it places epithelial TNFR1 inside the causal chain tested here.
Inflammation meets cellular fuel
In organoids made from young mice, TNF reduced new crypt budding and suppressed genes involved in mitochondria and fatty-acid metabolism. When the cells were challenged to oxidize palmitate, TNF reduced their maximum respiratory capacity. Aged intestinal stem and progenitor cells showed a related decline in their fatty-acid metabolism program.
This creates a bridge between two lines of aging research that are often discussed separately. Inflammation is not simply a background marker in the experiment, and mitochondrial decline is not merely an isolated defect inside an old cell. The new evidence supports a sequence in which inflammatory signaling can change the metabolic program that regenerative cells need to function.
That sequence also clarifies earlier mouse research from MIT. A 2018 Cell Stem Cell study found that a 24-hour fast increased fatty-acid oxidation and improved intestinal stem-cell regeneration in young and old mice. The new study approaches the same metabolic bottleneck from the opposite direction: rather than asking what turns fatty-acid oxidation up, it identifies systemic inflammation and TNFR1 signaling as forces that can turn it down.
What the intervention results do—and do not—show
Several interventions improved laboratory measures. Salicylate, aspirin, rapamycin and antibodies against TNF or interferon-gamma increased organoid formation in old mice under particular experimental conditions. A mitochondrial-fusion activator improved crypt budding in aged organoids, and compounds activating PPAR metabolic pathways partly protected young organoids from TNF.
Those findings should not be read as advice to take aspirin, fast, suppress TNF or use rapamycin for healthy aging. The experiments were conducted in mice or mouse-derived organoids, used research-specific dosing and endpoints, and did not test lifespan, healthspan or routine treatment in people. Systemic immune suppression and anti-inflammatory drugs can carry consequential risks, while inflammation also has necessary roles in defense and healing.
The intervention pattern is more informative as a consistency check on the mechanism. Genetic protection at TNFR1, antibody experiments, gene-expression changes, metabolic assays and partial rescue through mitochondrial or lipid pathways all point toward the same inflammation–metabolism connection. Yet interferon-gamma also mattered, the source of the relevant inflammatory signals remains unresolved, and some metabolic readouts changed while others did not.
A more precise target for translation
The most useful outcome is not a candidate anti-aging pill but a sharper translational question. Researchers can now ask whether an analogous TNF–TNFR1–fatty-acid-oxidation pathway operates in aging human intestinal tissue, which cell populations produce the signals, and whether preserving repair is possible without broadly disabling immune function.
The study also shows why regenerative aging cannot be reduced to either the cell or its surroundings. An old systemic environment altered young tissue, but removing one receptor from the target epithelium changed the outcome. That makes intestinal stem-cell aging a two-sided problem: the signals delivered by the body and the metabolic response permitted inside the cell.
For now, the evidence is strong within a multilayered mouse model and preliminary for human longevity. Its contribution is a testable mechanism linking chronic inflammatory tone to declining tissue renewal. Whether that mechanism can be measured safely, separated from normal immune function and altered beneficially in people remains the work ahead.
TENS Magazine conceptual illustration
